Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25502552 | 0.94 | CTSK (0.45) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL22906234 | 0.94 | CTSK (0.46) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL253303 | 0.94 | SIRT1 (0.46) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL253304 | 0.94 | SIRT1 (0.46) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL16572281 | 0.93 | CTSS (0.48) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL16504508 | 0.93 | CTSS (0.48) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL16572287 | 0.93 | CTSS (0.48) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL16504607 | 0.93 | CTSS (0.48) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL10316221 | 0.93 | CTSK (0.46) | CTSKCTSSCAPN1CA2CA1 | |
| SCHEMBL16504677 | 0.93 | CTSS (0.48) | CTSKCTSSCAPN1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655210-B2 | Compound for improving L-arginine bioavailability | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655210-B2 | Compound for improving L-arginine bioavailability | THE GENERAL HOSPITAL CORPORATION (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210206717-A1 | Compound for Improving L-Arginine Bioavailability | THE GENERAL HOSPITAL CORPORATION | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206717-A1 | Compound for Improving L-Arginine Bioavailability | ARG1, ARG2, NOS2 | CTSK 2605/4885CTSS 3852/4885CAPN1 3214/4885 |
| US-11655210-B2 | Compound for improving L-arginine bioavailability | ARG1, ARG2, NOS2 | CTSK 2605/4885CTSS 3852/4885CAPN1 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.